The drug ABARAN contains one active pharmaceutical ingredient (API):
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
This brand name is authorized in the following countries: Lithuania
This drug has been assigned below unique identifiers within the countries it is being marketed: